FDA Approves New BESREMi Pen for Easier Polycythemia Vera Treatment

PharmaEssentia USA Corporation has received FDA approval for its BESREMi Pen™ device. This new self-administration option aims to provide greater convenience for adult patients with polycythemia vera. The pen offers an alternative to the existing pre-filled syringe for administering ropeginterferon alfa-2b-njft.